Lamisil cream

Страна: Армения

Язык: английский

Источник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Активный ингредиент:

terbinafine (terbinafine hydrochloride)

Доступна с:

GlaxoSmithKline Consumer Healthcare S.A.

код АТС:

D01AE15

ИНН (Международная Имя):

terbinafine (terbinafine hydrochloride)

дозировка:

10mg/g

Фармацевтическая форма:

cream

Штук в упаковке:

15g aluminium tube, 15g laminated tube

Тип рецепта:

OTC

Статус Авторизация:

Registered

Дата Авторизация:

2020-01-09

Характеристики продукта

Global Drug Regulatory Affairs
LAMISIL1% CREAM
Terbinafine
SUMMARY OF PRODUCT CHARACTERISTICS
Property of GSK Consumer Healthcare S.A.
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of GSK Consumer Healthcare S.A.
CONTENTS
1.
NAME OF THE MEDICINAL PRODUCT
...............................................................................
3
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
..................................................... 3
3.
PHARMACEUTICAL FORM
....................................................................................................
3
4.
CLINICAL PARTICULARS
......................................................................................................
3
4.1.
Therapeutic indications
..................................................................................................
3
4.2.
Posology and method of administration
.........................................................................
3
4.3.
Contra-indications
..........................................................................................................
4
4.4.
Special warnings and precautions for use
......................................................................
4
4.5.
Interactions with other medicinal products and other forms of
interaction ................... 4
4.6.
Pregnancy and lactation
.................................................................................................
4
4.7.
Effects on ability to drive and use machines
................................................................. 5
4.8.
Undesirable effects
.........................................................................................................
5
4.9.
Overdose
........................................................................................................................
5
5.
PHARMACOLOGICAL PROPERTIES
....................................................................................
6
5.1.
Pharmacodynamic properties
.........................................